To Assess Skin Safety of Test Product(s) by Patch Test on Adult Healthy Human Subjects
NCT ID: NCT07109453
Last Updated: 2025-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
26 participants
INTERVENTIONAL
2025-08-25
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Assess Skin Safety of Test Product(s) by Patch Test on Adult Healthy Human Subjects.
NCT07065149
Skin Irritation Test of Ten Products
NCT05245383
Dermatological Evaluation of Topical Compatibility, Primary Skin Irritability, Accumulated Skin Irritability, and Dermal Sensitisation
NCT02419248
Dermatological Evaluation of Topical Compatibility, Primary Skin Irritability, Accumulated Skin Irritability, and Dermal Sensitisation
NCT03007498
50 Human Subject Repeat Insult Patch Test
NCT04498676
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
18 Test Products along with Positive and Negative Control
1. Deep Hydration Gel
2. Anti-Wrinkle Gel
3. Anti-Aging Gel
4. Under Eye Cream
5. Brightening Cream
6. Moisturizing Cream
7. Anti-Acne Serum
8. Face Toner
9. Anti-Aging Toner
10. Clear Glow Toner
11. Super Anti-Aging Serum
12. Sun Screen SPF50
13. Anti-Pigmentation Serum
14. Super Cleansing Cream
15. Root Revive Hair Serum
16. Root Nourishment Hair Oil
17. Anti-Acne Face Wash
18. Ever Glow Face Wash 0.04 gm/ml of each Test Products along with positive control (1% SLS) and negative controls will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.
18 Test Products along with positive and negative control
1\. Deep Hydration Gel 2. Anti-Wrinkle Gel 3. Anti-Aging Gel 4. Under Eye Cream 5. Brightening Cream 6. Moisturizing Cream 7. Anti-Acne Serum 8. Face Toner 9. Anti-Aging Toner 10. Clear Glow Toner 11. Super Anti-Aging Serum 12. Sun Screen SPF50 13. Anti-Pigmentation Serum 14. Super Cleansing Cream 15. Root Revive Hair Serum 16. Root Nourishment Hair Oil 17. Anti-Acne Face Wash 18. Ever Glow Face Wash 0.04 gm/ml of each Test Products along with positive control (1% SLS) and negative controls will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18 Test Products along with positive and negative control
1\. Deep Hydration Gel 2. Anti-Wrinkle Gel 3. Anti-Aging Gel 4. Under Eye Cream 5. Brightening Cream 6. Moisturizing Cream 7. Anti-Acne Serum 8. Face Toner 9. Anti-Aging Toner 10. Clear Glow Toner 11. Super Anti-Aging Serum 12. Sun Screen SPF50 13. Anti-Pigmentation Serum 14. Super Cleansing Cream 15. Root Revive Hair Serum 16. Root Nourishment Hair Oil 17. Anti-Acne Face Wash 18. Ever Glow Face Wash 0.04 gm/ml of each Test Products along with positive control (1% SLS) and negative controls will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
* Subject with normal Fitzpatrick skin type III to V (Human skin colour determination scale).
* Females of childbearing potential must have a self-reported negative pregnancy test.
* Subject who do not have any previous
* history of adverse skin conditions and are not under any medication likely to interfere with the results.
* Subject is in good general health as determined by
* the Investigator on the basis of medical history.
* Subjects is willing to maintain the test patches in designated positions for 24 Hours.
* Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.
* Subject must be able to understand and provide written informed consent to participate in the study.
* Subject is willing to refrain from vigorous physical exercise during the study period and follow all the instruction given.
* For Sensitive Skin Condition Only:
* Subject scoring greater than 30 for Section 2 - Sensitive v/s Resistant skin in modified Dr Baumann's\* skin type questionnaire.
* Subject with sensitive skin as confirmed by Lactic Acid Stinging Test.
Exclusion Criteria
* Medication which may affect skin response and/or past medical history.
* Subject having history of diabetes
* Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.
* Subject suffering from any active clinically significant skin diseases which may contraindicate.
* Subject having history of any skin diseases including eczema, atopic dermatitis or active cancer.
* Participation in any patch test for irritation or sensitization within the last four weeks.
* Subject having history of asthma or COPD (Chronic obstructive pulmonary disease).
* Use of any:
* Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application.
* Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application. iii. Systemic or topical corticosteroids at patch site within four (4) weeks of test product application (steroidal nose drops and/or eye drops are permitted)
* Topical drugs used at application site.
* Subject with Self-reported Immunological disorders such as HIV positive, AIDS and/or systemic lupus erythematous.
* Individual who has a medical condition or is taking or has taken a medication which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk.
* Subject with known allergy or sensitization to medical adhesives, bandages.
* Participation in other patch study simultaneously
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Skin Harmony Lifescience Pvt. Ltd
UNKNOWN
NovoBliss Research Pvt Ltd
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. Nayan Patel
Role: PRINCIPAL_INVESTIGATOR
NovoBliss Research Private Limited
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NB250037-SHL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.